Reaction

Thyroiditis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,941 reports · 60 co-occurring drugs

As of the last recalculation, Thyroiditis appears in 2,941 FAERS reports alongside 60 co-occurring drug terms. The strongest observed disproportionality signal is IPILIMUMAB (PRR 62.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ipilimumab	340	62.9	63.4
Nivolumab	556	50.0	50.2
Pembrolizumab	559	46.2	46.4
Minocycline	69	42.9	43.1
Amiodarone Hydrochloride	51	32.8	32.9
Durvalumab	83	29.7	29.8
Lenvatinib	131	29.5	29.6
Atezolizumab	134	25.5	25.6
Alemtuzumab	51	19.0	19.0
Methimazole	20	18.1	18.2
Axitinib	38	14.0	14.0
Paclitaxel (Aibumin-Bound)	128	11.5	11.5
Carboplatin	181	10.7	10.7
Paclitaxel	132	9.8	9.8
Lithium Carbonate	21	8.8	8.8
Encorafenib	12	8.6	8.6
Cabozantinib	57	8.5	8.6
Cefazolin	10	7.8	7.8
Febuxostat Tablets 40 Mg	11	7.7	7.7
Febuxostat Tablets 80 Mg	11	7.7	7.7
Lubiprostone	10	7.5	7.5
Cefazolin Sodium	12	7.1	7.1
Valganciclovir Hydrochloride Powder,	11	6.4	6.4
Bosutinib	8	6.3	6.3
Pemetrexed Disodium	33	6.2	6.2
Fexofenadine Hcl	8	6.1	6.1
Regorafenib	10	6.1	6.1
Pemetrexed	18	6.0	6.0
Bevacizumab	97	5.7	5.7
Lithium	20	5.6	5.6
Lithium Bromatum	20	5.6	5.6
Sotalol Hydrochloride	13	5.6	5.6
Pitavastatin Calcium	8	5.5	5.5
Febuxostat	12	5.1	5.1
Trametinib	17	5.0	5.0
Loperamide Hydrochloride Oral	7	4.9	4.9
Everolimus Tablets	11	4.7	4.7
Sunitinib Malate	25	4.5	4.5
Eplerenone	8	4.4	4.4
Loperamide Hcl	8	4.4	4.4
Erlotinib	6	4.4	4.4
Dabrafenib	13	4.4	4.4
Epoprostenol	8	4.3	4.3
Pazopanib Hydrochloride	16	4.2	4.2
Sorafenib	12	4.1	4.1
Tolvaptan	8	3.9	3.9
Cisplatin	41	3.8	3.8
Entecavir	6	3.6	3.6
Ribavirin	32	3.6	3.6
Erlotinib Hydrochloride	6	3.4	3.4
Selexipag	12	3.3	3.3
Suvorexant	6	3.3	3.3
Vemurafenib	5	2.9	2.9
Fexofenadine Hydrochloride	9	2.9	2.9
Peginterferon Alfa-2A	22	2.9	2.9
Gemcitabine Hydrochloride	21	2.8	2.8
Ranolazine	4	2.7	2.7
Osimertinib	11	2.4	2.4
Dasatinib	11	2.1	2.1
Tirzepatide	18	0.8	0.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.